What effect does Wegovy have on the liver?

Does Wegovy actually help with fatty liver disease?

The short answer is yes, and the evidence has been building for several years. Fatty liver disease sits on a spectrum. At the milder end is MASLD (metabolic dysfunction-associated steatotic liver disease), where excess fat accumulates in liver cells but inflammation is limited. Further along that spectrum is MASH (formerly called NASH) where the liver becomes inflamed and begins to scar. It is MASH that carries a real risk of cirrhosis if left unmanaged.

Semaglutide's mechanism is relevant here. As a GLP-1 receptor agonist it slows gastric emptying and reduces appetite, which leads to meaningful weight loss. Fat stored in the liver is often among the first to be mobilised when body weight falls. Separately, GLP-1 receptors are expressed in liver tissue, and researchers have observed direct anti-inflammatory effects in hepatic cells, though the weight-loss effect is considered the dominant driver of liver improvement. If you want a fuller picture of how semaglutide affects the liver, including what the clinical data shows about hepatic fat reduction, that detail is covered separately.

Clinical trials published in The Lancet found that patients receiving 2.4mg weekly semaglutide showed significant reductions in liver fat and, in people with MASH, meaningful rates of fibrosis regression compared with placebo. Those findings supported the MHRA's conditional approval on 3 July 2026, announced on GOV.UK, for semaglutide to treat MASH in adults with moderate-to-advanced fibrosis. It was a landmark decision; no licensed treatment for this condition had previously existed in the UK.

What does the MASH approval mean for someone considering Wegovy for weight loss?

The two indications are distinct. When someone starts Wegovy through a weight-management service, the licensing criteria applied are those for obesity, BMI thresholds, weight-related comorbidities, and clinical judgement. The MASH indication exists alongside that, but it is a separate clinical pathway managed by hepatologists and gastroenterologists, not routine weight-loss prescribing.

In practice, this matters in two ways. First, if you have already been told you have fatty liver disease or MASH, your liver specialist needs to be involved in any decision about semaglutide, the NHS semaglutide medicines page outlines relevant considerations, and your full medication history is part of that review. Second, if a prescriber identifies elevated liver enzymes or known liver disease during your consultation, that is clinically relevant information that shapes the recommendation. It is not a barrier in every case, but it must be declared.

For people whose liver disease is mild and weight-related, losing weight through Wegovy can itself reduce liver fat significantly. That benefit is well established. Whether your specific situation qualifies (and which indication applies) is a conversation for your clinical team. Our prescribers at nume (sorry, at nume) review each consultation personally; a real clinician reads your answers, not automated software. If there is any complexity around liver health, they will advise on the appropriate next step, which may include a referral to your GP.

Are there any liver-related risks to know about with Wegovy?

Wegovy is generally considered safe in people with mild-to-moderate liver impairment, though it is not recommended for those with severe hepatic impairment, and the Mounjaro and Wegovy SmPCs on the electronic Medicines Compendium contain the authoritative detail on contraindications. Many patients reasonably want to know whether Wegovy affects the liver at all, and the straightforward answer is that for most people with healthy liver function, no harmful effect has been observed at therapeutic doses. The most common side effects are gastrointestinal (nausea, loose stools, indigestion) and are not liver-specific, though severe nausea affecting food intake over time is worth reporting to your prescriber.

Pancreatitis is a known but uncommon risk with GLP-1 medicines generally, flagged in an MHRA Drug Safety Update in January 2026. Pancreatic and liver symptoms can sometimes feel similar (upper abdominal pain, discomfort that reaches the back) so the guidance is unambiguous: seek medical attention promptly for severe, persistent stomach pain rather than waiting to see if it settles. You can report any suspected side effect through the MHRA Yellow Card scheme, which is open to patients as well as healthcare professionals.

One practical note on storage: Wegovy pens need to be kept refrigerated between 2 and 8°C. The fridge door is a common place people store them, though the Patient Information Leaflet gives the full guidance on temperature windows, including how long a pen can remain unrefrigerated once in use. Follow that leaflet closely, and flag any storage questions to your prescriber or pharmacist.

Who should talk to a specialist before starting Wegovy?

Anyone with a confirmed diagnosis of MASH, cirrhosis, or liver enzyme levels flagged as significantly elevated should discuss semaglutide with a hepatologist before starting treatment anywhere. There is detailed guidance available on what Wegovy does to the liver, covering both the beneficial effects seen in trials and the precautions relevant to people with pre-existing hepatic conditions, and separately it is worth reading about whether Wegovy can affect your liver if you want to understand the specific mechanisms and monitoring considerations in plain terms. Wegovy for weight management is not an alternative to specialist liver care, the two may run alongside each other, but that requires coordination.

Pregnancy, breastfeeding, and trying to conceive are all situations where Wegovy is not recommended, and anyone planning a family should read up on Wegovy and pregnancy before starting or continuing treatment, because the drug should be stopped before attempting conception and the wash-out period should be discussed with your doctor. Under-18s are not within the licensed population.

For people without an established liver diagnosis who simply want to understand whether Wegovy is appropriate for their situation, the consultation process at num's weight-loss treatment service is the right starting point. You describe your medical history in full; a prescriber reviews it the same day. There is no obligation to proceed. If you have specific questions about liver health and how it intersects with treatment options, our team is reachable through the contact page or you can browse common questions while you decide. Patients often ask about the effects Wegovy can have on the heart, which is covered in its own dedicated guide for anyone who wants to explore the cardiovascular side of treatment alongside the liver-related questions.